Home

Dyne Therapeutics, Inc. - Common Stock (DYN)

13.82
-0.59 (-4.09%)
NASDAQ · Last Trade: Jun 16th, 10:04 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · June 16, 2025
Curious about the stocks that are showing activity after the closing bell on Monday?chartmill.com
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
Via Chartmill · June 16, 2025
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boostinvestors.com
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
Via Investor's Business Daily · April 21, 2025
Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 11, 2025
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risksbenzinga.com
On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...
Via Benzinga · March 12, 2025
Looking Into Dyne Therapeutics's Recent Short Interestbenzinga.com
Via Benzinga · October 22, 2024
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Pathbenzinga.com
JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates.
Via Benzinga · March 21, 2025
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?benzinga.com
Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated Approval by 2026.
Via Benzinga · January 10, 2025
Peering Into Dyne Therapeutics's Recent Short Interestbenzinga.com
Via Benzinga · September 30, 2024
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higherbenzinga.com
Via Benzinga · September 3, 2024
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophybenzinga.com
Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful functional improvements.
Via Benzinga · September 3, 2024
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Via Benzinga · September 3, 2024
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Buildinginvestors.com
The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results.
Via Investor's Business Daily · September 3, 2024
Nasdaq Dips Over 2%; US Construction Spending Falls In Julybenzinga.com
Via Benzinga · September 3, 2024
Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimatesbenzinga.com
Via Benzinga · September 3, 2024
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · September 3, 2024
Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity?talkmarkets.com
Find out the significance of the
Via Talk Markets · August 21, 2024
Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday?benzinga.com
A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to increase bets on a more significant 50
Via Benzinga · August 13, 2024
DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024investorplace.com
DYN stock results show that Dyne Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Detailsbenzinga.com
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.
Via Benzinga · July 14, 2024
Chart Of The Day: Dyne Therapeutics - Deeply Discountedtalkmarkets.com
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
Via Talk Markets · July 10, 2024
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · June 12, 2024
Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks Reactbenzinga.com
U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September.
Via Benzinga · June 12, 2024
The 3 Most Undervalued Biotech Stocks to Buy in June 2024investorplace.com
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via InvestorPlace · June 4, 2024
Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 22, 2024